Fig. 6From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvantsEvolution of VEGF-specific IgG antibodies and VEGF/VEGFR2 blockade in patients submitted to long-term re-immunizations. Samples, taken at different time points, came from twelve patients (depicted by their trial code name) with an overall survival longer than 45 weeks (approximately 1 year). Antibody titers and VEGF/VEGFR2 blockade percentages are shown as black dots and red bars, respectively. Week 0 is pre-vaccination and week 13 is one week after finishing the trial vaccinations. Cut-off values that define the positivity for IgG antibodies (black discontinued line) and VEGF/VEGFR2 blockade (red discontinued line) are shown for each patientBack to article page